These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23113477)

  • 1. Risk, responsibility, and generic drugs.
    Kesselheim AS; Avorn J; Greene JA
    N Engl J Med; 2012 Nov; 367(18):1679-81. PubMed ID: 23113477
    [No Abstract]   [Full Text] [Related]  

  • 2. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM; Curfman G
    JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
    [No Abstract]   [Full Text] [Related]  

  • 3. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 4. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH; Annas GJ
    N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
    [No Abstract]   [Full Text] [Related]  

  • 5. The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.
    Greene JA; Watkins ES
    N Engl J Med; 2015 Sep; 373(12):1087-9. PubMed ID: 26287749
    [No Abstract]   [Full Text] [Related]  

  • 6. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 7. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 8. The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation.
    Morten CJ; Kesselheim AS; Ross JS
    J Law Med Ethics; 2019 Dec; 47(4):783-787. PubMed ID: 31957583
    [No Abstract]   [Full Text] [Related]  

  • 9. Court rules generic drug companies not responsible for adverse outcomes.
    Kouros N
    Monash Bioeth Rev; 2013 Sep; 31(2):23-4. PubMed ID: 24844072
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceutical promotion to physicians and First Amendment rights.
    Kesselheim AS; Avorn J
    N Engl J Med; 2008 Apr; 358(16):1727-32. PubMed ID: 18420505
    [No Abstract]   [Full Text] [Related]  

  • 11. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 12. Teaching clinicians about drugs--50 years later, whose job is it?
    Avorn J
    N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
    [No Abstract]   [Full Text] [Related]  

  • 13. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 14. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry.
    Burshtein S
    Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562
    [No Abstract]   [Full Text] [Related]  

  • 15. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
    Carlson J
    Mod Healthc; 2014 Jun; 44(26):20-2. PubMed ID: 25134408
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of Wyeth v. Levine on FDA regulation of prescription drugs.
    Ausness RC
    Food Drug Law J; 2010; 65(2):247-83, i-ii. PubMed ID: 24475542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who is now responsible for discovering and warning about adverse effects of generic drugs?
    Kesselheim AS; Green MD; Avorn J
    JAMA; 2013 Sep; 310(10):1023-4. PubMed ID: 23922000
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 19. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
    Hemphill Kraus EJ
    N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.